-
公开(公告)号:ES2342116T3
公开(公告)日:2010-07-01
申请号:ES06841410
申请日:2006-12-18
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: ANDRES-GIL JOSE IGNACIO , ALCAZAR-VACA MANUEL JESUS , LINARES DE LA MORENA MARIA LOURDES , MARTINEZ GONZALEZ SONIA , OYARZABAL SANTAMARINA JULEN , PASTOR-FERNANDEZ JOAQUIN
IPC: C07D401/12 , A61K31/497 , A61P25/00
Abstract: Un compuesto de acuerdo con la fórmula general (I) **(Ver fórmula)** una sal farmacéuticamente aceptable de adición de ácido o base de la misma, una forma estereoquímicamente isómera de la misma, una forma de N-óxido de la misma o una sal de amonio cuaternario de la misma, en donde: V es un radical naftilo, en donde una unidad CH en el resto naftilo puede estar reemplazada opcionalmente por un átomo N; Y es un radical bivalente de fórmula (II) (II) **(Ver fórmula)** en donde A es un átomo de nitrógeno o de carbono; m es un número entero igual a cero 1 ó 2; R4 se selecciona del grupo de hidrógeno; alquilo y fenilcarboxilalquilo; R5 se selecciona del grupo de hidrógeno y halo; X1, X2 son cada uno, independientemente uno de otro, un enlace covalente, un radical hidrocarbonado (C1-8) saturado o insaturado, en donde una o más unidades bivalentes -CH2- y/o una o más unidades monovalentes CH3 pueden estar reemplazadas opcionalmente por una unidad fenilo respectiva bivalente o monovalente; y en donde uno o más átomos de hidrógeno pueden estar reemplazados por un radical seleccionado del grupo de oxo; (C1-3)alquiloxi; halo; ciano; nitro; formilo; hidroxi; amino; trifluorometilo; mono- y di((C1-3)alquil)amino; carboxi; y tio; p, q son cada uno, independientemente uno de otro, un número entero igual a 1 o 2; Q1, Q2 son cada uno, independientemente uno de otro, un radical seleccionado del grupo de hidrógeno; -NR1R2; Pir; -OR3 y Het; en donde dos radicales -OR3 pueden considerarse juntos para formar un radical bivalente -O-(CH2)r-O- en donde r es un número entero igual a 1, 2 ó 3; R1 y R2 son cada uno, independientemente uno de otro, un radical seleccionado del grupo de hidrógeno; alquilo; alquenilo; alquinilo; arilo; arilalquilo; alquilcarbonilo; alquenilcarbonilo; alquiloxi; alquiloxialquilo; alquiloxicarbonilo; alquiloxialquilcarbonilo; alquiloxicarbonilalquilo; alquiloxicarbonilalquilcarbonilo; alquilsulfonilo; arilcarbonilo; ariloxialquilo; arilalquilcarbonilo; arilsulfonilo; Het; Het-alquilo; Het-alquilcarbonilo; Het-carbonilo; Het-carbonilalquilo; alquil-NRaRb; carbonil-NRaRb; carbonilalquil-NRaRb; alquilcarbonil-NRaRb; y alquilcarbonilalquil-NRaRb; en donde Ra y Rb se seleccionan, cada uno independientemente, del grupo de hidrógeno, alquilo, alquilcarbonilo, alquiloxialquilo, alquiloxicarbonilalquilo, arilo, arilalquilo, Het y alquil-NRcRd, en donde Rc y Rd son, cada uno independientemente, hidrógeno o alquilo; Pir es un radical que contiene al menos un N, por el cual está unido al radical X, seleccionados del grupo de pirrolidinilo; imidazolidinilo; pirazolidinilo; piperidinilo; piperazinilo; pirrolilo; pirrolinilo; imidazolinilo; pirrazolinilo; pirrolilo; imidazolilo; pirazolilo; triazolilo; azepilo; diazepilo; morfolinilo; tiomorfolinilo; indolilo; isoindolilo; indolinilo; indazolilo; bencimidazolilo; y 1,2,3,4-tetrahidro-isoquinolinilo; en donde cada radical Pir está sustituido opcionalmente por 1, 2 o 3 radicales seleccionados del grupo de hidroxi; halo; oxo; (C1-3)alquilo; trifluorometilo; fenilo; bencilo; pirrolidinilo; y piridiniloxi; R3 es un radical seleccionado del grupo de hidrógeno; alquilo; arilo; arilalquilo; Het; y Het-alquilo; Het es un radical heterocíclico seleccionados del grupo de pirrolidinilo; imidazolidinilo; pirazolidinilo; piperidinilo; piperazinilo; pirrolilo; pirrolinilo; imidazolinilo; pirrazolinilo; pirrolilo; imidazolilo; pirazolilo; triazolilo; piridinilo; piridazinilo; pirimidinilo; pirazinilo; triazinilo; azepilo; diazepilo; morfolinilo; tiomorfolinilo; indolilo; isoindolilo; indolinilo; indazolilo; bencimidazolilo; 1,2,3,4-tetrahidro-isoquinolinilo; furilo; tienilo; oxazolilo; isoxazolilo; tiazolilo; tiadiazolilo; isotiazolilo; dioxolilo; ditianilo; tetrahidrofurilo; tetrahidropiranilo; quinolinilo; isoquinolinilo; quinoxalinilo; benzoxazolilo; bencisoxazolilo; benzotiazolilo; bencisotiazolilo; benzofuranilo; benzotienilo; benzopiperidinilo; cromenilo; e imidazo[1,2-a]piridinilo; en donde cada radical Het está sustituido opcionalmente por uno o más radicales seleccionados del grupo de halo; oxo; (C1-3)alquilo; (C1-3)alquilcarbonilo; (C1-3)alqueniltio; imidazolil-(C1-3)alquilo; y (C1-3)alquiloxicarbonilo; arilo es naftalenilo o fenilo, sustituido cada uno opcionalmente con 1, 2 o 3 sustituyentes, independientemente cada uno de otro, seleccionados del grupo de oxo; (C1-3)alquilo; (C1-3)alquiloxi; halo; ciano; nitro; formilo; hidroxi; amino; trifluorometilo; mono- y di((C1-3)alquil)amino; carboxi; y tio; alquilo es un radical hidrocarbonado saturado lineal o ramificado que tiene de 1 a 8 átomos de carbono; o es un radical hidrocarbonado saturado cíclico que tiene de 3 a 7 átomos de carbono; o es un radical hidrocarbonado saturado cíclico que tiene de 3 a 7 átomos de carbono unido a un radical hidrocarbonado saturado lineal o ramificado que tiene de 1 a 8 átomos de carbono; en donde cada radical está sustituido opcionalmente en uno o más átomos de carbono con uno o más radicales seleccionados del grupo de oxo; (C1-3)alquiloxi; halo; ciano; nitro; formilo; hidroxi; amino; carboxi; y tio; alquenilo es un radical alquilo como se ha definido anteriormente, que tiene adicionalmente uno o más enlaces dobles; alquinilo es un radical alquilo como se ha definido anteriormente, que tiene adicionalmente uno o más enlaces triples; y arilalquilo es un radical alquilo como se ha definido anteriormente, que tiene adicionalmente uno o más grupos CH3 reemplazados por fenilo.
-
公开(公告)号:IS2618B
公开(公告)日:2010-04-15
申请号:IS6591
申请日:2002-10-25
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: EMELEN KRISTOF VAN , BRUYN MARCEL FRANS LEOPOLD DE , ALCAZAR-VACA MANUEL JESUS , ANDRES-GIL JOSE IGNACIO , FERNANDEZ-GADEA FRANCISCO JAVIER , MATESANZ-BALLESES-TEROS MARIA ENCARNACIO , BARTOLOME-NEBREDA JOSE MANUEL
IPC: C07D491/056 , C07D491/06 , A61K31/435 , A61K31/436 , A61K31/4545 , A61K31/513 , A61K31/5383 , A61P1/00 , A61P1/14 , C07D411/04 , C07D491/04 , C07D491/052 , C07D497/04 , C07D498/04
-
公开(公告)号:EA012628B1
公开(公告)日:2009-10-30
申请号:EA200702530
申请日:2006-05-17
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: FERNANDEZ-GADEA FRANCISCO JAVIER , ANDRES-GIL JOSE IGNACIO , TRABANCO-SUAREZ ANDRES AVELINO , CID-NUNEZ JOSE MARIA , MEGENS ANTONIUS ADRIANUS HENDRIKUS PETRUS
IPC: C07D405/06 , C07D493/04 , C07D495/04
Abstract: Изобретениеотноситсяк новымтетрациклическимпроизводнымтетрагидрофурана, содержащимв боковойцепигруппуциклическогоаминаи обладающимсродствомсвязыванияв отношениисеротониновыхрецепторов, вчастности 5-HTи 5-HTрецепторов, ив отношениидопаминовыхрецепторов, вчастностидопаминовых Dрецепторов, фармацевтическимкомпозициям, включающимсоединениясогласноизобретению, ихприменениюв качествелекарственногосредства, вчастностидляпрофилактикии/илилечениярядапсихическихи неврологическихрасстройств, вособенностинекоторыхпсихических, сердечно-сосудистыхи желудочно-кишечныхрасстройств, ик способамихполучения. Соединениясогласнонастоящемуизобретениюмогутбытьпредставленыобщейформулой (I) ивключаюттакжеихфармацевтическиприемлемыеаддитивныесолис кислотойилиоснованием, стереохимическиизомерныеформы, N-оксидныеформыи четвертичныеаммониевыесоли, гдезначениязаместителейопределеныв п.1.
-
公开(公告)号:CA2664112A1
公开(公告)日:2008-06-12
申请号:CA2664112
申请日:2007-12-04
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: ALCAZAR-VACA MANUEL JESUS , ANDRES-GIL JOSE IGNACIO , LINDERS JOANNES THEODORUS MARIA , DAUTZENBERG FRANK MATTHIAS
IPC: C07D471/10 , A61K31/4427 , A61K31/5386 , A61P3/04 , A61P3/06 , A61P25/22 , A61P25/24 , C07D498/10
Abstract: The present invention concerns aryl and heteroaryl substituted diaza-spir o-pyridinone derivatives having antagonistic melanin-concentrating hormone ( MCH) activity, in particular MCH-1 activity according to the general Formula (I), a pharmaceutically acceptable acid or base addition salt thereof, an N -oxide form thereof or a quaternary ammonium salt thereof, wherein the varia bles are defined in Claim 1. It further relates to their preparation, compos itions comprising them and their use as a medicine. The compounds according to the invention are useful for the prevention and/or treatment of psychiatr ic disorders, including but not limited to anxiety, eating disorders, mood d isorders, such as bipolar disorders and depression, psychoses, such as schiz ophrenia, and sleeping disorders; obesity; diabetes; sexual disorders and ne urological disorders.
-
公开(公告)号:DE60315311T2
公开(公告)日:2008-04-17
申请号:DE60315311
申请日:2003-08-12
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: ANDRES-GIL JOSE IGNACIO , BARTOLOME-NEBREDA JOSE MANUEL , ALVAREZ-ESCOBAR ROSA MARIA , BAKKER MARGARETHA HENRICA , MEGENS ANTONIUS ADRIANUS HENDR
IPC: C07D498/04 , A61K31/424 , A61K31/496 , A61K31/5377 , A61P3/04 , A61P25/02 , A61P25/16 , A61P25/18 , A61P25/22 , A61P25/24 , A61P43/00 , C07D261/00 , C07D311/00
Abstract: The invention concerns substituted tricyclic isoxazoline derivatives according to Formula (I), the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof and the N-oxide form thereof, more in particular tricyclic dihydrobenzopyranoisoxazoline, dihydroquinolinoisoxazoline, dihydronaphthalenoisoxazoline and dihydrobenzothiopyranoisoxazoline derivatives substituted on the phenylpart of the tricyclic moiety with at least one radical that is attached to the phenyl radical by a carbon-carbon bond as well as processes for their preparation, pharmaceutical compositions comprising them and their use as a medicine, in particular for treating depression, anxiety, movement disorders, psychosis, Parkinson's disease and body weight disorders including anorexia nervosa and bulimia, wherin all variables are defined in claim 1. (I) The compounds have surprisingly been shown to have selective serotonine (5-HT) reuptake inhibitor activity in combination with additional alpha2-adrenocptor antagonist activity and show a strong antidepressant and/or anxiolytic activity and/or antipsychotic and/or a body weight control activity without being sedative. Also, in view of their selective serotonine (5-HT) reuptake inhibitor as well as alpha2-adrenoceptor antagonist activity, compounds according to the invention are also suitable for treatment and/or prophylaxis in diseases where either one of the activities alone or the combination of said activities may be of therapeutic use.
-
公开(公告)号:CA2659923A1
公开(公告)日:2008-04-17
申请号:CA2659923
申请日:2007-10-10
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: VEGA-RAMIRO JUAN ANTONIO , PASTOR-FERNANDEZ JOAQUIN , MARTINEZ GONZALEZ SONIA , OYARZABAL SANTAMARINA JULEN , DRINKENBURG WILHELMUS HELENA IGNATIUS MARIA , DELGADO-JIMENEZ FRANCISCA , ANDRES-GIL JOSE IGNACIO , ALCAZAR-VACA MANUEL JESUS , LINARES DE LA MORENA MARIA LOURDES
IPC: C07D401/12 , A61K31/501 , A61P25/00 , C07D241/20
Abstract: The present invention concerns substituted pyrazinone derivatives accordi ng to the general Formula (I) a pharmaceutically acceptable acid or base add ition salt thereof, a stereochemically isomeric form thereof, an N-oxide for m thereof or a quaternary ammonium salt thereof, wherein the variables are d efined in Claim 1, having selective 2C-adrenoceptor antagonist activity. It further relates to their preparation, compositions comprising them and their use as a medicine. The compounds according to the invention are usefull for the prevention and/or treatment of central nervous system disorders, mood d isorders, anxiety disorders, stress-related disorders associated with depres sion and/or anxiety, cognitive disorders, personality disorders, schizoaffec tive disorders, Parkinson's disease, dementia of the Alzheimer's type, chron ic pain conditions, neurodegenerative diseases, addiction disorders, mood di sorders and sexual dysfunction.
-
公开(公告)号:AU2007306382A1
公开(公告)日:2008-04-17
申请号:AU2007306382
申请日:2007-10-10
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: DRINKENBURG WILHELMUS HELENA I , VEGA-RAMIRO JUAN ANTONIO , MORENA MARIA LOURDES LINARES DE LA , SANTAMARINA JULEN OYARZABAL , PASTOR-FERNANDEZ JOAQUIN , DELGADO-JIMENEZ FRANCISCA , ALCAZAR-VACA MANUEL JESUS , ANDRES-GIL JOSE IGNACIO , GONZALEZ SONIA MARTINEZ
IPC: C07D401/12 , A61K31/501 , A61P25/00 , C07D241/20
Abstract: The present invention concerns substituted pyrazinone derivatives according to the general Formula (I) a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof, an N-oxide form thereof or a quaternary ammonium salt thereof, wherein the variables are defined in claim 1, having selective 2C-adrenoceptor antagonist activity. It further relates to their preparation, compositions comprising them and their use as a medicine. The compounds according to the invention are useful for the prevention and/or treatment of central nervous system disorders, mood disorders, anxiety disorders, stress-related disorders associated with depression and/or anxiety, cognitive disorders, personality disorders, schizoaffective disorders, Parkinson's disease, dementia of the Alzheimer's type, chronic pain conditions, neurodegenerative diseases, addiction disorders, mood disorders and sexual dysfunction.
-
公开(公告)号:PT1636239E
公开(公告)日:2007-09-24
申请号:PT04741649
申请日:2004-05-26
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: BARTOLOME-NEBREDA JOSE M , ANDRES-GIL JOSE IGNACIO
IPC: C07D498/04 , A61K31/4355 , A61K31/436 , A61K31/5383 , A61P25/18 , C07D491/04
-
公开(公告)号:AU2002244717B2
公开(公告)日:2007-07-19
申请号:AU2002244717
申请日:2002-02-13
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: PASTOR-FERNANDEZ JOAQUIN , STECKLER THOMAS HORST WOLFGANG , HEYLEN GODELIEVE IRMA CHRISTIN , ANDRES-GIL JOSE IGNACIO , ALCAZAR-VACA MANUEL JESUS , MEGENS ANTONIUS ADRIANUS HENDR , BAKKER MARGARETHA HENRICA MARI , LANGLOIS XAVIER JEAN MICHEL , CID-NUNEZ JOSE MARIA , FERNANDEZ-GADEA FRANCISCO JAVI
IPC: C07D498/04 , A61K31/454 , A61K31/495 , A61K31/496 , A61K31/538 , A61P3/04 , A61P25/00 , A61P25/18 , A61P25/22 , A61P25/24 , C07D261/20 , C07D498/14 , C07D519/00
Abstract: The invention concerns substituted isoxazolines derivatives according to Formula (I): wherein X=CH?2#191, N-R 7 , S or O, R 1 , R 2 and R 3 are certain specific substituents, Pir is an optionally substituted piperidyl or piperazyl radical and R3 represents an optionally substituted aromatic homocyclic or heterocyclic ring system including a partially or completely hydrogenated hydrocarbon chain of maximum 6 atoms long with which the ring system is attached to the Pir radical and which may contain one or more heteroatoms selected from the group of O, N and S; a process for their preparation, pharmaceutical compositions comprising them and their use as a medicine, in particular for the treatment of depression and/of anxiety and disorders of body weight. The compounds according to the invention have surprisingly been shown to have a serotonine (5-HT) reuptake inhibitor activity in combination with additional alpha2-adrenoceptor antagonist activity and show a strong anti-depressant activity without being sedative. Compounds according to the invention arc also suitable for treating patients with anxiety disorders and disorders of body weight. The invention also relates to novel combination of substituted isoxazolines derivatives having anti-depressant activity and/or anxiolytic activity and/or body weight control activity with antidepressants, anxiolytics and/or antipsychotics to improve efficacy and/or onset of action
-
公开(公告)号:AU2006328558A1
公开(公告)日:2007-06-28
申请号:AU2006328558
申请日:2006-12-18
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: MACRITCHIE JACQUELINE , ALVAREZ-ESCOBAR ROSA MARIA , SIMPSON DONALD , DAUTZENBERG FRANK MATTHIAS , ALCAZAR-VACA MANUEL JESUS , SANTAMARINA JULEN OYARZABAL , ANDRES-GIL JOSE IGNACIO , GONZALEZ SONIA MARTINEZ
IPC: C07D241/20 , A61K31/497 , A61P31/18 , C07D403/10
Abstract: The present invention concerns aryl and heteroaryl substituted pyrazinone derivatives having antagonistic melanin-concentrating hormone (MCH) activity, in particular MCH-1 activity according to the general Formula (I) a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof, an N-oxide form thereof or a quaternary ammonium salt thereof, wherein the variables are defined in Claim 1. It further relates to their preparation, compositions comprising them and their use as a medicine. The compounds according to the invention are useful for the prevention and/or treatment of psychiatric disorders, including but not limited to anxiety, eating disorders, mood disorders, such as bipolar disorders and depression, psychoses, such as schizophrenia, and sleeping disorders; obesity; diabetes; sexual disorders and neurological disorders.
-
-
-
-
-
-
-
-
-